Anti-thrombotic therapy with or without revascularisation in Japanese patients with stable coronary artery disease and atrial fibrillation: post-hoc analysis of the AFIRE trial
A post-hoc analysis of the AFIRE trial showed that in patients at high thrombotic risk with a history of revascularisation, antithrombotic treatment with rivaroxaban monotherapy had better safety and efficacy compared with the combination of rivaroxaban and antiplatelet therapy, according to a study performed by Dr. Takashi Noda and colleagues of Tohoku University, Graduate School of Medicine, reported in the April 1 issue of EuroIntervention.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
